Osteoprotegerin (OPG): A Multifaceted Player in Cardiovascular Diseases

A new review article published in the journal Cardiovascular Innovations and Applications discusses the multifaceted role of Osteoprotegerin (OPG) in cardiovascular diseases (CVDs).

OPG, a glycoprotein belonging to the tumor necrosis factor superfamily, primarily functions in bone metabolism by suppressing the formation and activation of osteoclasts. However, growing evidence highlights its physiological significance, particularly in the context of CVDs.

Growing evidence highlights OPG's physiological significance, particularly in the context of cardiovascular diseases.

OPG's Involvement in Vascular Pathology

Elevated OPG levels are linked to conditions such as atherosclerosis, arterial calcification, and heart failure, indicating its involvement in cardiac remodeling and vascular pathology. OPG plays a role in regulating calcification and vascular homeostasis by restricting the transdifferentiation of vascular smooth muscle cells into osteogenic phenotypes.

Aberrant OPG expression is also observed in illnesses that elevate cardiovascular risk, including aortic valve stenosis, chronic renal disease, and diabetes.

Molecular Interactions and Clinical Impact

Beyond its structural regulatory capacity, OPG interacts with inflammatory and apoptotic mediators like RANKL and TRAIL within signaling pathways that connect bone metabolism, inflammation, and vascular dysfunction.

Elevated circulating OPG and altered OPG/TRAIL ratios have been associated with myocardial infarction, left ventricular remodeling, and increased mortality.

Future Directions

This review provides molecular and clinical insights into OPG's diverse functions in CVDs, suggesting its potential as a regulator of disease etiology and a predictive biomarker.

Understanding the OPG/RANKL/TRAIL axis holds promise for facilitating targeted therapy and improving risk stratification in cardiovascular medicine.